Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
PREZCOBIX™ now available for Canadians living with HIV

Janssen Inc. announced today that PREZCOBIX™ (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. The new treatment option combining a protease inhibitor with a boosting agent reduces the number of pills required to manage HIV.

Published
13 hours ago
From
Newswire.ca
First Single-Tablet PI Regimen With Darunavir and TAF at 48 Weeks

Cobicistat-boosted darunavir plus tenofovir alafenamide (TAF) and emtricitabine (FTC) yielded less bone and renal toxicity than darunavir/cobicistat plus tenofovir/emtricitabine (TDF/FTC) in randomized a phase 2 trial.

Published
16 September 2014
From
NATAP
Long acting HIV drugs to be developed

HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of ‘pill fatigue’.

Published
15 September 2014
From
University of Liverpool press release
New medicines in development give hope to patients with HIV/AIDS

America’s biopharmaceutical research companies are currently developing 44 medicines and vaccines for HIV/AIDS treatment and prevention, according to the latest Medicines in Development report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Published
11 September 2014
From
Pharmaceutical Research and Manufacturers of America
New HIV Drug, BMS-986001, Safe and Effective in Treatment-Naive Patients

BMS-986001, a novel thymidine analog NRTI (nucleoside reverse transcriptase inhibitor) being developed by Oncolys BioPharma, when combined with efavirenz (Sustiva, Stocrin) and lamivudine (3TC, Epivir), was found to have comparable efficacy to tenofovir (Viread) in treatment-naive patients living with HIV, according to phase-2b study results presented by Samir K. Gupta, M.D., M.S., at ICAAC 2014 in Washington, D.C.

Published
10 September 2014
From
The Body
Drug-level study shows feasibility of long-acting integrase inhibitor cabotegravir

A pharmacokinetic (PK) analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC, confirmed that the long-acting HIV integrase inhibitor cabotegravir (formerly GSK1265744) reaches adequate target levels in the blood, setting the stage for efficacy trials for HIV treatment and pre-exposure prophylaxis (PrEP).

Published
10 September 2014
From
HIVand hepatitis.com
New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

An experimental single-tablet regimen containing a new version of tenofovir (tenofovir alafenamide or TAF) and the HIV protease inhibitor darunavir (Prezista) worked as well as a similar regimen containing the older tenofovir disoproxil fumarate (TDF) formulation,but it had less detrimental effects on kidney function and bone density, as study presented at the recent ICAAC conference heard.

Published
09 September 2014
From
HIVandhepatitis.com
EU marketing authorization for ViiV Healthcare HIV drug Triumeq

The European Commission has granted marketing authorization for ViiV Healthcare’s Triumeq(dolutegravir 50mg/abacavir 600mg/lamivudine 300mg) tablets for the treatment of HIV in adults and adolescents aged 12 years and older.

Published
04 September 2014
From
Pharma Letter
The Role of Triumeq in HIV Treatment

The approval of Triumeq, the single-tablet coformulation of abacavir, lamivudine and the integrase inhibitor dolutegravir, is an important step forward for antiretroviral therapy. Whereas all of the previously approved single-tablet regimens (STRs) contain tenofovir (Viread), which some people can't take, usually because of kidney disease, Triumeq does not contain tenofovir.

Published
04 September 2014
From
The Body
Aiming For HIV's Weak Spot - The new generation of gp120 entry inhibitors

A small molecule (green) binds within a cavity on the HIV protein gp120. Amino acid residues that contribute only to binding affinity are colored blue, and those that contribute strongly to binding as well as the protein's conformational change are ...

Published
02 September 2014
From
C&EN - Chemical and Engineering News
← First12345...78Next →

Filter by country